Related Experiment Video
Updated: Jun 3, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature
Qiongqian Li1, Tongze Cai1, Xiaoming Zheng1
1Department of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
Abstract:
We report a case showing that lorlatinib is effective in treating EML4-ALK-positive low-grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4-ALK fusion and promoting new ideas for the study of EML4-ALK targets in ovarian cancer.
Insights
Lorlatinib shows effectiveness in treating advanced low-grade serous ovarian cancer (LGSO) with brain metastasis. This study provides early clinical evidence for ALK inhibitors in LGSO patients with EML4-ALK fusion.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Low-grade serous ovarian cancer (LGSO) is a rare subtype.
- Intracranial metastasis presents a significant treatment challenge in LGSO.
- The role of ALK inhibitors in LGSO is not well-established.
Purpose of the Study:
- To report a case of successful treatment of EML4-ALK-positive LGSO with intracranial metastasis.
- To evaluate the efficacy of lorlatinib in this specific patient population.
- To explore the potential of ALK inhibitors for LGSO treatment.
Main Methods:
- Case report of a patient with EML4-ALK-positive LGSO and brain metastasis.
- Treatment with lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor.
- Clinical and radiological assessment of treatment response.
Main Results:
- Lorlatinib demonstrated significant effectiveness in treating the intracranial metastasis.
- The patient showed a positive clinical response to lorlatinib therapy.
- This case suggests potential clinical benefit of ALK inhibitors in LGSO.
Conclusions:
- Lorlatinib may be a viable treatment option for EML4-ALK-positive LGSO with intracranial metastasis.
- This finding supports further investigation into ALK inhibitors for ovarian cancer.
- Highlights the importance of molecular profiling in LGSO treatment strategies.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
11:09Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Published on: July 13, 2010
